Turalio ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
34Neurofibromatosis1

34. Neurofibromatosis


Clinical trials : 133 Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02390752
(ClinicalTrials.gov)
April 29, 201517/3/2015Phase I Trial of Turalio(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)Phase I Trial of Turalio(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)Neurofibroma, Plexiform;Precursor Cell Lymphoblastic Leukemia-Lymphoma;Leukemia, Promyelocytic, Acute;SarcomaDrug: TuralioNational Cancer Institute (NCI)NULLRecruiting3 Years35 YearsAll54Phase 1United States